Skip to main content
. 2022 Aug 10;22(11):1565–1576. doi: 10.1016/S1473-3099(22)00420-0

Figure 1.

Figure 1

Consort diagram for study 2019nCoV-101 (part 2): booster dosing of group B participants

Group A received two doses of placebo. Group B received two doses of NVX-CoV2373 (5 μg SARS-CoV-2 rS with 50 μg Matrix-M adjuvant). Group C received one dose of NVX-CoV2373 (5 μg SARS-CoV-2 rS with 50 μg Matrix-M adjuvant) and one dose of placebo. Group D received two doses of NVX-CoV2373 (25 μg SARS-CoV-2 rS with 50 μg Matrix-M adjuvant). Group E received one dose of NVX-CoV2373 (25 μg SARS-CoV-2 rS with 50 μg Matrix-M adjuvant) and one dose of placebo. *Patients who received three doses in the corresponding group. Patients were analysed according to treatment received.